Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol in Pre-Motor and Symptomatic Parkinson's Disease
NCT03775096Phase 2Active, not recruiting
- Start
- Apr 2019
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carvedilol in Parkinson's disease (PD) and REM sleep behavior disorder (RBD). Primary endpoint: 123I-MIBG reuptake changes at 26 weeks. Started Apr 2019; status: active, not recruiting.
02
Drugs
carvedilol
03
Conditions
Parkinson's disease (PD)REM sleep behavior disorder (RBD)
Beyond the preview
Go deeper on NCT03775096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03775096.